Last reviewed 2026-05-19 · How we verify

AZD4205 and itraconazole

Dizal Pharmaceuticals · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

AZD4205 and itraconazole is a Small molecule drug developed by Dizal Pharmaceuticals. It is currently in Phase 1 development.

AZD4205 is a drug being studied in a Phase 1 clinical trial to assess its interactions with itraconazole and carbamazepine. The study, titled "Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine," aims to evaluate the pharmacokinetics of AZD4205 when co-administered with these two medications.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	AZD4205 and itraconazole
Sponsor	Dizal Pharmaceuticals
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AZD4205 and itraconazole CI brief — competitive landscape report
AZD4205 and itraconazole updates RSS · CI watch RSS
Dizal Pharmaceuticals portfolio CI

Frequently asked questions about AZD4205 and itraconazole

What is AZD4205 and itraconazole?

AZD4205 and itraconazole is a Small molecule drug developed by Dizal Pharmaceuticals.

Who makes AZD4205 and itraconazole?

AZD4205 and itraconazole is developed by Dizal Pharmaceuticals (see full Dizal Pharmaceuticals pipeline at /company/dizal-pharmaceuticals).

What development phase is AZD4205 and itraconazole in?

AZD4205 and itraconazole is in Phase 1.

Manufacturer: Dizal Pharmaceuticals — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing